Pharming Group (PHAR) Competitors $14.07 -0.53 (-3.63%) Closing price 03:58 PM EasternExtended Trading$14.07 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. ACLX, ADMA, ARWR, MENS, MIRM, MLTX, MTSR, PTGX, AAPG, and LNTHShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Ascentage Pharma Group International Lantheus Arcellx (NASDAQ:ACLX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Is ACLX or PHAR more profitable? Pharming Group has a net margin of -2.19% compared to Arcellx's net margin of -329.93%. Pharming Group's return on equity of -3.31% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-329.93% -43.04% -27.41% Pharming Group -2.19%-3.31%-1.78% Which has more risk and volatility, ACLX or PHAR? Arcellx has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ACLX or PHAR? 96.0% of Arcellx shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 8.4% of Arcellx shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ACLX or PHAR? Pharming Group has higher revenue and earnings than Arcellx. Pharming Group is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M41.09-$107.35M-$3.42-23.39Pharming Group$297.20M3.24-$11.84M-$0.13-108.23 Do analysts prefer ACLX or PHAR? Arcellx presently has a consensus price target of $114.31, suggesting a potential upside of 42.92%. Pharming Group has a consensus price target of $30.00, suggesting a potential upside of 113.22%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ACLX or PHAR? In the previous week, Arcellx had 2 more articles in the media than Pharming Group. MarketBeat recorded 7 mentions for Arcellx and 5 mentions for Pharming Group. Arcellx's average media sentiment score of 0.98 beat Pharming Group's score of 0.53 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArcellx beats Pharming Group on 9 of the 16 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$3.13B$5.81B$10.33BDividend YieldN/A2.37%5.86%4.62%P/E RatioN/A21.3676.9326.98Price / Sales3.24251.85450.4089.35Price / Cash196.9645.4837.2260.63Price / Book4.339.6913.836.37Net Income-$11.84M-$52.92M$3.29B$271.46M7 Day Performance-4.93%1.44%0.93%2.35%1 Month Performance13.56%6.03%5.31%7.78%1 Year Performance77.20%12.89%84.25%32.27% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.253 of 5 stars$14.07-3.6%$30.00+113.2%+84.6%$1.00B$297.20M0.00280ACLXArcellx2.1452 of 5 stars$71.11-2.1%$114.31+60.7%-2.0%$4.03B$107.94M-20.7980ADMAADMA Biologics3.5503 of 5 stars$16.42-2.7%$27.67+68.5%-16.8%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1618 of 5 stars$27.17-6.6%$43.14+58.8%+45.6%$4.02B$3.55M-21.23400Trending NewsInsider TradeAnalyst RevisionGap UpMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageHigh Trading VolumeMIRMMirum Pharmaceuticals3.1428 of 5 stars$77.39+1.7%$74.13-4.2%+81.5%$3.82B$336.89M-63.96140MLTXMoonLake Immunotherapeutics2.5632 of 5 stars$61.12+2.8%$74.43+21.8%+0.4%$3.82BN/A-21.992MTSRMetseraN/A$35.10-2.1%$59.00+68.1%N/A$3.77BN/A0.0081Analyst UpgradePTGXProtagonist Therapeutics2.0992 of 5 stars$56.19-7.2%$67.20+19.6%+31.9%$3.77B$434.43M80.27120Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$41.04+1.3%N/AN/A$3.76B$134.35M0.00600News CoverageHigh Trading VolumeLNTHLantheus4.5526 of 5 stars$53.63-2.0%$91.60+70.8%-51.8%$3.72B$1.53B14.26700Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ACLX Competitors ADMA Competitors ARWR Competitors MENS Competitors MIRM Competitors MLTX Competitors MTSR Competitors PTGX Competitors AAPG Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
